On Wednesday, Windtree Therapeutics, Inc. (NASDAQ:WINT) released topline results from its Phase 2b SEISMiC Extension Study of istaroxime for patients in early cardiogenic shock due to heart failure. The study is focused on the effects of istaroxime on blood pressure, cardiac function, and other parameters over 96 hours of close monitoring, with the final visit at 30 days. The study met its primary endpoint by significantly improving systolic blood pressure over six hours, with the combined istaroxime group performing significantly better than the placebo group. Systolic blood pressure is the p…